文献速递关节外科

全髋关节置换术中关节腔内注射局部麻醉药是否降低患者报告的疼痛评分或阿片类药物消耗量

Does the Use of an Intra-Articular Local Anesthetic Injection During Total Hip Arthroplasty Reduce Patient Reported Pain Scores or Patient Opioid Consumption?
PubMed 文献 · J Arthroplasty · 2021-12-17

该回顾性研究纳入571例初次全髋关节置换术患者,比较接受200 mg罗哌卡因关节腔内注射与未接受者的疼痛评分、阿片类药物消耗量和活动能力。结果显示注射组活动时平均疼痛评分更高(P=0.024),且需要更高吗啡毫克当量;注射组在16小时至28小时疼痛显著上升,24小时至32小时吗啡毫克当量增加;两组活动水平、活动时间和行走距离无差异。结论认为关节腔内注射似乎不能降低疼痛评分或阿片类药物消耗量,需进一步研究。

要点

  • 接受200 mg罗哌卡因关节腔内注射的患者活动时平均疼痛评分更高(P=0.024)。
  • 注射组需要更高吗啡毫克当量,24小时至32小时显著增加(P=0.003至P=0.012)。
  • 两组活动水平、活动时间和行走距离无差异。

核心结论

  • 关节腔内注射似乎不能降低全髋关节置换术患者的术后疼痛评分或吗啡毫克当量。
  • 需要更多研究关注关节腔内罗哌卡因的使用和疗效,尤其是功能结局和性别差异。

研究设计与样本

  • 回顾性综述了在单一机构接受初次全髋关节置换术的571例患者。
  • 患者按是否接受200 mg罗哌卡因关节腔内注射分为两组。
  • 主要结局指标包括疼痛评分、吗啡毫克当量、行走距离和活动时间。

主要发现

  • 注射组活动时平均疼痛评分高于对照组(P=0.024)。
  • 注射组需要更高的吗啡毫克当量。
  • 注射组疼痛从16小时开始显著上升(P=0.0009)并持续至28小时(P=0.032)。
  • 注射组吗啡毫克当量在24小时至32小时增加(P=0.003至P=0.012)。
  • 两组活动水平、活动时间和行走距离无差异,200 mg罗哌卡因关节腔内注射在男性中似乎导致更高疼痛评分和更高阿片类药物剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性研究。
  • 原文为单一机构研究。
  • 需要更多研究关注关节腔内罗哌卡因的使用和疗效,尤其是功能结局和性别差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During primary total hip arthroplasty (THA), some surgeons use an intra-articular injection (IAI) containing 200 mg ropivacaine to target postoperative pain. There is no clear consensus on the efficacy of an IAI alone. The purpose of this study is to evaluate the effect of a 200 mg ropivacaine IAI on pain scores, opioid consumption, and mobility for primary THA patients. METHODS: We retrospectively reviewed 571 patients who underwent primary THA at a single institution. Patients were grouped according to those who received a 200 mg ropivacaine IAI and those who did not. Primary outcome measures for this study included pain scores, morphine milligram equivalents (MMEs) dosed, distance of ambulation achieved, and time to ambulation. RESULTS: The intervention group reported higher average pain scores with activity than the control group (P = .024). The intervention group also required higher MMEs. When striated by hour, a statistically significant uptick in pain started at 16 hours (P = .0009) and persisted to 28 hours (P = .032) in patients receiving a 200 mg ropivacaine IAI. This correlated with an increase in MMEs seen at hour 24 through 32 (P = .003 to P = .012). Level of ambulation, time to ambulation, and distance ambulated did not differ between groups. An IAI of 200 mg ropivacaine also appeared to lead to higher pain scores and higher opioid doses in males. CONCLUSION: The IAI does not appear to reduce postoperative pain scores or MMEs dosed for THA patients. More research is needed to look at the utilization and efficacy of intra-articular ropivacaine, especially focusing on functional outcomes and gender differences.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Geiselmann MT, Goldberg LK, Strecker SE, et al. Does the Use of an Intra-Articular Local Anesthetic Injection During Total Hip Arthroplasty Reduce Patient Reported Pain Scores or Patient Opioid Consumption? J Arthroplasty. 2021. PMID: 34929336. doi:10.1016/j.arth.2021.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。